Does Immunotherapy Offer Survival Gain in Older NSCLC Patients? Does Immunotherapy Offer Survival Gain in Older NSCLC Patients?

Contrary to clinical trial results, the survival benefit of checkpoint inhibitors in the real-world setting is lower among older people with NSCLC, who make up a large proportion of patients.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news